NCT00697632已完成1 期
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 19
- 主要终点
- Safety and tolerability
研究概览
简要总结
In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.
详细描述
MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients.
In this study, MGCD265 is orally administered on a daily basis to patients with advanced malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced metastatic or unresectable malignancy that is refractory to standard therapy and/or existing therapies are not likely to achieve clinical benefit, and/or the patient declines to receive standard treatment such as chemotherapy.
- •Evaluable disease;
- •Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least 4 weeks before the start of therapy;
- •Recovery from the adverse effects ≤ grade 1;
- •Acceptable ECOG status 0, 1, or 2;
- •Life expectancy greater than 3 months following study entry;
- •Adequate laboratory values;
- •For patients enrolling in the four expansion cohorts:
- •NSCLC patients must meet criteria for MET and/or Axl expression or,
- •HNSCC patients must meet criteria for MET and/or Axl expression or,
- •NSCLC patients must meet criteria for amplification of the MET gene locus, defined MET mutations, or rearrangements involving the AXL or MET gene locus or;
- •Patients with tumor types such as HNSCC, papillary renal carcinoma, gastric adenocarcinoma, and other solid tumors must meet criteria for amplification of the MET gene locus, defined MET mutations, or rearrangements involving the AXL or MET gene locus
排除标准
- •Uncontrolled concurrent illness;
- •History of cardiovascular illness;
- •QTc > 470 msec (including subjects on medication);
- •Left ventricular ejection fraction (LVEF) < 50%;
- •Immunocompromised subjects;
- •History of bone marrow transplant;
- •Lung tumor lesions with increased likelihood of bleeding;
- •Symptomatic or uncontrolled brain metastases;
- •Unable to swallow oral medications or with pre-existing gastrointestinal disorders.
研究组 & 干预措施
1
Experimental
干预措施: MGCD265 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: 1 year [Anticipated]
次要结局
- Pharmacokinetics(1 year [Anticipated])
- Pharmacodynamics(1 year [Anticipated])
- Clinical response(1 year [Anticipated])
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced MalignanciesAdvanced MalignanciesNCT00679133Mirati Therapeutics Inc.47
终止
1 期
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid TumorsMalignant Solid TumorNCT06771921Genmab3
招募中
1 期
Safety of AM-928 Infusion in Advanced Solid TumorsAdvanced Solid TumorNCT05687682AcadeMab Biomedical Inc.38
已完成
1 期
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaAdvanced Solid TumorsChronic Lymphocytic LeukemiaNCT02316197Merck KGaA, Darmstadt, Germany31
已完成
1 期
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) PatientsLeber Hereditary Optic NeuropathyNCT02064569GenSight Biologics19